Company Directory

Global pharma company in immunology, vaccines, and oncology

GSK is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of medicines and vaccines. Its pipeline and portfolio span respiratory and immunology, oncology, HIV (through its specialist subsidiary ViiV Healthcare), and infectious diseases including vaccines. The company operates major UK sites including its global R&D hub at Stevenage Bioscience Catalyst, manufacturing facilities at Barnard Castle, Ware, and Montrose, and its global headquarters in London's Knowledge Quarter.

Silica encapsulation platform eliminating cold chain for biologics

EnsiliTech is a biotechnology company developing ensilication, a patented platform technology that encases vaccines, antibodies, and other biologics within a silica matrix to render them thermally stable without refrigeration. The technology is applicable to existing and new biopharmaceutical formulations, enabling storage and transport at temperatures up to 50°C. EnsiliTech is developing applications across vaccines and monoclonal antibody therapeutics, with partners including the Centre for Process Innovation.

Fibroblast immunology platform targeting cancer and inflammatory disease

Mestag Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapies targeting activated fibroblasts to modulate immune responses in cancer and inflammatory disease. Its lead programme, MST-0312, is a bispecific antibody designed to induce tertiary lymphoid structures in solid tumours to drive anti-tumour immunity. A second programme targets a stromal inhibitory receptor to address inflammatory conditions including rheumatoid arthritis, IBD, and lupus.

Target discovery platform and antibody-based therapies for oncology

Oxford BioTherapeutics is an Oxford-based clinical-stage oncology company discovering and developing first-in-class antibody-based cancer therapies. Its proprietary platform identifies novel membrane protein targets directly from patient tumour samples, enabling the development of ADCs, immuno-oncology antibodies, T-cell engagers, and CAR-T targets. The company licenses discovered targets and development candidates to major pharmaceutical partners including Bristol Myers Squibb, Roche, GSK, and Boehringer Ingelheim.

Antibody discovery platform identifying therapeutics from resilient individuals

Alchemab Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for neurodegenerative diseases, oncology, and immunology. Its platform combines deep B cell sequencing and machine learning to identify naturally protective antibodies from individuals resilient to specific diseases. The company's lead programme for amyotrophic lateral sclerosis entered Phase 1 trials following a licensing agreement with Eli Lilly. Alchemab operates from London with research laboratories in Cambridge.

Clinical-stage antibody-drug conjugate developer for cancer

Iksuda Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates for difficult-to-treat solid and haematological cancers. Its ADC platform combines proprietary stable bioconjugation chemistry with tumour-selective payload activation to improve therapeutic index. The company's lead candidate, IKS014, is a HER2-targeting ADC in Phase 1 clinical trials. Iksuda also develops novel payload classes including its first-in-class protein alkylating agents. The company operates from Newcastle Helix with additional facilities in the United States.

Antibody fragment drug conjugate platform for solid tumour oncology

Antikor Biopharma is a pre-clinical stage biotechnology company developing antibody fragment drug conjugates for the treatment of solid tumours. The company's proprietary platform uses smaller antibody fragments rather than whole antibodies to achieve improved tumour penetration and faster systemic clearance compared to conventional antibody-drug conjugates. Antikor's lead programme targets cMET-expressing solid tumours and has demonstrated efficacy and safety data in advanced pre-clinical models.

Engineered bacteria to remodel the tumour microenvironment

Neobe Therapeutics is a UK synthetic biology company developing programmable live biotherapeutics that colonise solid tumours and disrupt the local microenvironment to enable immune cell infiltration. The platform engineers tumour-colonising bacteria to break down stromal barriers that exclude immune cells, aiming to increase response rates to existing immunotherapies in patients with immune-cold tumours. Lead programmes target colorectal and pancreatic cancers, with first-in-human trials planned for 2027.

Viral vector platform for solid tumour immunotherapy

Akamis Bio is a clinical-stage oncology company developing oncolytic adenoviral therapeutics for solid tumours. Its platform delivers immunotherapeutic payloads directly to tumour sites following intravenous dosing, enabling tumour-localised expression of proteins including CD40 agonist antibodies and cytokines. Lead programme NG-350A is in a Phase 1b trial for locally advanced rectal cancer, having received FDA Fast Track Designation; NG-641 is in Phase 1 combination studies in advanced epithelial tumours.

AI platform for in silico antibody discovery

Antiverse is a Cardiff-based company using machine learning to identify diverse and rare antibody candidates from next-generation sequencing data of naïve and immune repertoires. Its AI-augmented discovery platform analyses NGS data in silico to shortlist effective and developable antibodies, claiming a tenfold improvement in hit rates compared to conventional approaches. The platform is already in use with large pharmaceutical companies and is being expanded to a broader customer base targeting oncology, cardiovascular, and respiratory indications.

Monoclonal antibodies for viral infectious disease

RQ Biotechnology is a passive immunisation company discovering and developing long-acting monoclonal antibodies to provide immediate protection against viral infections in immunocompromised and vulnerable populations. Founded by members of the UK COVID-19 Antibody Taskforce and co-founded with LifeArc, the company's pipeline spans influenza, RSV, and CMV. Its SARS-CoV-2 antibody programme was licensed to AstraZeneca and has progressed through Phase III trials.

KnotBody therapeutics for ion channel and GPCR diseases

Maxion Therapeutics is a biotechnology company developing a pipeline of KnotBody therapeutics for diseases driven by ion channel and G protein-coupled receptor dysfunction. The platform combines naturally occurring mini-proteins with antibodies to generate potent, selective and long-acting biologics against target classes previously inaccessible to antibody drug discovery. Lead programme MAX001 is in preclinical development for inflammatory diseases including atopic dermatitis. The company raised £58 million in a Series A financing in March 2025.